Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Amgen, the most common co-covered peer. They are better corroborated than the beat average, carrying 10.5 original sources each against 3.4 for the same window.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Amgen, the most common co-covered peer. They are better corroborated than the beat average, carrying 10.5 original sources each against 3.4 for the same window. Across a 122-day span, the pace is roughly 0.1 stories per week. The 6 average consequence score is below the beat benchmark of 6.2 in the same window. NovoCure appears in 2 tracked Biotech stories published from February 27, 2026 through June 28, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 398 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NovoCure. Shared-story counts are live from our verified record — not editorial picks.
Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Source: The Motley Fool · Brendan Coffey (us)
The final quarter of 2025 revealed a sector-wide shift toward operational discipline and high-margin product expansion among leading biotech and pharma entities. Key players like Indivior and Pacira reported significant volume growth in flagship therapies while successfully navigating patent challenges and portfolio optimizations.
NovoCure is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
